BACLOSIGN 10 Tablet is a therapeutic formulation containing Baclofen 10 mg, a well-established centrally acting muscle relaxant widely prescribed for the management of spasticity due to neurological disorders. Baclofen belongs to the gamma-aminobutyric acid (GABA) analog class and functions by inhibiting the transmission of nerve signals in the spinal cord. It is particularly effective in reducing involuntary muscle stiffness, rigidity, and painful spasms that arise from upper motor neuron lesions. BACLOSIGN 10 is extensively used in chronic conditions such as multiple sclerosis, spinal cord injury or disease, cerebral palsy, and post-stroke muscle spasticity.

The mechanism of action of Baclofen involves selective agonism of GABA-B receptors in the central nervous system. By binding to these receptors, Baclofen inhibits the release of excitatory neurotransmitters like glutamate and aspartate, thereby reducing neuronal excitability. This action helps restore the balance between excitatory and inhibitory signals in the spinal cord and brain, resulting in decreased muscle tone, improved range of motion, and relief from spasticity. BACLOSIGN 10 plays a key role in improving motor function, enhancing patient mobility, and reducing discomfort in patients who experience chronic spasticity.

The pharmacokinetics of Baclofen support its use as an oral medication in tablet form. After administration, BACLOSIGN 10 is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations reached within two to three hours. The bioavailability of Baclofen is approximately 70 to 80 percent, and it readily crosses the blood-brain barrier to exert its therapeutic effect. It is primarily excreted through the kidneys, and its half-life ranges between two and six hours, making multiple daily doses necessary in most treatment regimens. BACLOSIGN 10 is usually prescribed in two or three divided doses per day to maintain optimal plasma levels and avoid peak-related side effects.